Language:
Password reminder
No account yet? Register Free
About Us Advertising Info Contact Us Client Login
labmedica.com
Genetic Testing
Features Subscription Partner Sites Journal Info
FOCUS DIAGNOSTICS, INC.THE BINDING SITESANYO EUROPE LTD

Genomic Pioneer Factor Underlies Breast Cancer Progression

By Labmedica International staff writers
Posted on 08 Dec 2011


The presence of a unique genomic pioneer factor, can guide the response to estrogen in breast cancer cells.

The use of various molecular and immunofluorescent techniques has identified a pioneer factor known as Pre-B-cell leukemia homeobox 1 (PBX1) which can determine the risk of the spread of cancer in patients with estrogen receptor alpha (ERα)-positive breast cancer.

Scientists at the Dartmouth-Hitchcock Norris Cotton Cancer Center (Lebanon, NH, USA) assessed the prognostic value of PBX1 in breast cancer by performing a meta-analysis using breast tumor expression studies. Pioneer factors are an emerging class of chromatin remodelers with the capacity to modulate cellular identity as they set the stage by defining the genomic regions accessible for transcription factors.

The profile of PBX1 recruitment and chromatin accessibility across the genome of breast cancer cells was accomplished through chromatin immunoprecipitation sequencing (ChIP-seq) and formaldehyde-assisted isolation of regulatory elements sequencing (FAIRE-seq). This revealed that PBX1 is loaded and promotes chromatin openness at specific genomic locations through its capacity to read specific epigenetic signatures. The results also demonstrated that PBX1 directly modulates chromatin compaction at discrete genomic regions to promote the recruitment of the transcription factor ERα, driving the proliferative response to estrogen in breast cancer cells.

The authors concluded that their results reveal the intricate interplay between distinct pioneer factors required for the implementation of specific transcriptional response to estrogen in breast cancer and distinguishes PBX1 as a prognostic marker. Mathieu Lupien, PhD, the principal investigator said, "This work may rapidly translate to the clinic because PBX1 could likely serve as a prognostic marker for ERα-positive breast cancer progression. It also highlights the potential therapeutic benefit of developing means to antagonize pioneer factors such as PBX1 to prevent breast cancer progression. The study was published in November 2011 in the open access journal Public Library of Science Genetics.

Related Links:

Dartmouth-Hitchcock Norris Cotton Cancer Center





Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
Free digital version edition of LabMedica International sent by email on regular basis
Free print version of LabMedica International magazine
(available only outside USA and Canada).
Free and unlimited access to back issues of LabMedica International in digital format
Free LabMedica International Newsletter sent every 2 weeks containing the latest news
Free breaking news sent via email
Free access to Events Calendar
Free access to LinkXpress new product services
REGISTRATION IS FREE AND EASY!


Click here to Register

Sign in: Registered website members
Username: Password:
Forgot username/password? Click here!
Sign in: Registered magazine subscribers
Subcode: Last Name:
What is SUBCODE?

ADVERTISEMENT
GLOBETECH PUBLISHING



Lab Software
Lab Software
Electronic Pipettes
Electronic Pipettes
Face Shield
Face Shield

More Products

AACC
CELLAVISION AB

Latest Genetic Testing News

LinkXpress
Click for LinkXpress
Reader Inquiry Service
Enter code to receive information:
Where I can find code?
Featured Whitepaper
ELGA LABWATER:
ELGA ensures largest latam lab is working night and day

Download Whitepaper
VISION-SCIENCES, INC.
Events
Journals of Clinical Laboratory update
23 Jun 2012 - 24 Jun 2012


FIME 2012 – Florida International Medical Exhibition.
08 Aug 2012 - 10 Aug 2012


ECI - European Congress of Immunology
05 Sep 2012 - 08 Sep 2012


More events
Latest Issue

View Digital Edition
Subscribe / Renew
GREINER-BIO-ONE'
GLOBETECH PUBLISHING
PURITAN MEDICAL
INOVA DIAGNOSTICS INC
BRAND GMBH + CO
BioPorto Diagnostics
EUROIMMUN AG
  labmedica.com Copyright © 2000-2012 Globetech Media. All rights reserved.
Privacy Policy